Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Breast Neoplasms 20Pancreatic Neoplasms 19Carcinoma, Non-Small-Cell Lung 17Ovarian Neoplasms 16Fallopian Tube Neoplasms 12Triple Negative Breast Neoplasms 10Neoplasm Metastasis 10Carcinoma, Ovarian Epithelial 10Unspecified Adult Solid Tumor, Protocol Specific 8Neoplasms 7Lung Neoplasms 7Endometrial Neoplasms 7Esophageal Neoplasms 6Brenner Tumor 6Breast Neoplasms, Male 6Stomach Neoplasms 5Melanoma 5Squamous Cell Carcinoma of Head and Neck 4Peritoneal Neoplasms 3Gallbladder Neoplasms 3Cholangiocarcinoma 3Adenocarcinoma of Lung 3Adenocarcinoma 3Uterine Cervical Neoplasms 2Urinary Bladder Neoplasms 2Salivary Gland Neoplasms 2Prostatic Neoplasms 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Lymphoma, Non-Hodgkin 2Leukemia, Lymphocytic, Chronic, B-Cell 2

Interventions

folfirinox 1Taxes 1Oxaliplatin 1Leucovorin 1Irinotecan 1Gemcitabine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Pancreatic Ductal Adenocarcinoma (PDAC) × Taxes × Clear all
NCT06182072 2025-10-01

ProAgio in Pancreatic Ductal Adenocarcinoma (PDAC)

ProDa BioTech, LLC

Phase 1 Recruiting
46 enrolled
Gastrointestinal

Pancreatic Ductal Adenocarcinoma (PDAC)

Data powered by HemOnc (CC BY 4.0) Colophon âš¡